Global Pancreatic Cancer Therapeutics Market Share Analysis 2016-2021
©
According to the report "Pancreatic Cancer Market", published by Market Data Forecast, the global market is projected to reach USD 2.99 billion by 2021, at a CAGR of 7.54% from 2016 to 2021.
For full report refer to http://www.marketdataforecast.com/market-reports/global-pancreatic-cancer-market-1277/
Pancreatic cancer is caused by the uncontrolled growth of cells in the pancreas. This abnormal, unrestrained growth of cells results in the formation of lumps of tissue, widely referred to as tumors. The presence of tumors prevents the normal functioning of pancreas. The occurrence and mortality rate of pancreatic cancer is more in men than in women. SEER estimates that pancreatic cancer accounts for around seven percent of the total cancer deaths in the US annually. While total cancer incidence and death rates are decreasing, the incidence and death rates for pancreatic cancer are rapidly burgeoning. Pancreatic cancer is projected to overtake colorectal cancer to become the second top cause of cancer-related death in the United States around 2020. Also, pancreatic cancer is the only major cancer with a five-year relative survival rate in the single digits, which is about a lowly 8%.
Free sample of the report is available at http://www.marketdataforecast.com/market-reports/global-pancreatic-cancer-market-1277/request-sample
Having less than five-year survival, the pancreatic cancer market has one of the highest unmet therapy needs in the oncology market across the globe. Clearly, this is also the most challenging aspect that this market needs to address. Given the nature of pancreatic cancer, treatments often return insufficient results. This challenge is yet another barrier to the growth of this market. Technologies are yet to develop fully for the timely diagnosis of this cancer type, which results in the diagnosis of majority of pancreatic cancer patients at an advanced stage of the disease. This explains the high mortality rates associated with pancreatic cancer. Estimates show that only a small percentage, that is about 12% to 15% of the patients is diagnosed early enough to be treated with surgical procedures, drugs, and chemotherapy.
Request Customization at http://www.marketdataforecast.com/market-reports/global-pancreatic-cancer-market-1277/customize-report
Product Segmentation:
Based on type of treatment
• Surgery
• Chemotherapy
• Radiation Therapy
• Others
Based on type
• Exocrine Pancreas Cancer
• Endocrine Pancreas Cancer
Based on End-users
• Hospitals
• Clinics
• Research Institutes
• Others
Geographical Segmentation
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa
Enquire more about the report at http://www.marketdataforecast.com/market-reports/global-pancreatic-cancer-market-1277/inquire
Key players in the pancreatic cancer market include Eli Lilly, Amgen, Inc., Celgene Corp., F. Hoffmann-La Roche, Clovis Oncology Inc., Pfizer, Novartis AG, Threshold Pharmaceuticals Inc., Aduro BioTech Inc., Infinity Pharmaceuticals Inc. and NewLink Genetics Corp.
Buy now https://www.marketdataforecast.com/cart/buy-now/global-pancreatic-cancer-market-1277
About us
Market Data Forecast is a firm working in the areas of market research and business intelligence. We have rich experience in research across major industry segments like Healthcare, Agriculture, Food & Beverages etc. and we cater to the needs of both individual and corporate clients. Our research services contribute to key business areas like business process improvement, key decision making and developing appropriate corporate strategy. We are truly committed to our clients and other stakeholders for providing customized research services of the highest quality all the while being an organisation that’s trusted for its integrity, respected for its accountability, and admired for its excellence, by both clients and competitors alike.
Contact Us:
Abhishek Shukla
Sales Manager
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 9985550206
Mail: abhishek@marketdataforecast.com
For full report refer to http://www.marketdataforecast.com/market-reports/global-pancreatic-cancer-market-1277/
Pancreatic cancer is caused by the uncontrolled growth of cells in the pancreas. This abnormal, unrestrained growth of cells results in the formation of lumps of tissue, widely referred to as tumors. The presence of tumors prevents the normal functioning of pancreas. The occurrence and mortality rate of pancreatic cancer is more in men than in women. SEER estimates that pancreatic cancer accounts for around seven percent of the total cancer deaths in the US annually. While total cancer incidence and death rates are decreasing, the incidence and death rates for pancreatic cancer are rapidly burgeoning. Pancreatic cancer is projected to overtake colorectal cancer to become the second top cause of cancer-related death in the United States around 2020. Also, pancreatic cancer is the only major cancer with a five-year relative survival rate in the single digits, which is about a lowly 8%.
Free sample of the report is available at http://www.marketdataforecast.com/market-reports/global-pancreatic-cancer-market-1277/request-sample
Having less than five-year survival, the pancreatic cancer market has one of the highest unmet therapy needs in the oncology market across the globe. Clearly, this is also the most challenging aspect that this market needs to address. Given the nature of pancreatic cancer, treatments often return insufficient results. This challenge is yet another barrier to the growth of this market. Technologies are yet to develop fully for the timely diagnosis of this cancer type, which results in the diagnosis of majority of pancreatic cancer patients at an advanced stage of the disease. This explains the high mortality rates associated with pancreatic cancer. Estimates show that only a small percentage, that is about 12% to 15% of the patients is diagnosed early enough to be treated with surgical procedures, drugs, and chemotherapy.
Request Customization at http://www.marketdataforecast.com/market-reports/global-pancreatic-cancer-market-1277/customize-report
Product Segmentation:
Based on type of treatment
• Surgery
• Chemotherapy
• Radiation Therapy
• Others
Based on type
• Exocrine Pancreas Cancer
• Endocrine Pancreas Cancer
Based on End-users
• Hospitals
• Clinics
• Research Institutes
• Others
Geographical Segmentation
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa
Enquire more about the report at http://www.marketdataforecast.com/market-reports/global-pancreatic-cancer-market-1277/inquire
Key players in the pancreatic cancer market include Eli Lilly, Amgen, Inc., Celgene Corp., F. Hoffmann-La Roche, Clovis Oncology Inc., Pfizer, Novartis AG, Threshold Pharmaceuticals Inc., Aduro BioTech Inc., Infinity Pharmaceuticals Inc. and NewLink Genetics Corp.
Buy now https://www.marketdataforecast.com/cart/buy-now/global-pancreatic-cancer-market-1277
About us
Market Data Forecast is a firm working in the areas of market research and business intelligence. We have rich experience in research across major industry segments like Healthcare, Agriculture, Food & Beverages etc. and we cater to the needs of both individual and corporate clients. Our research services contribute to key business areas like business process improvement, key decision making and developing appropriate corporate strategy. We are truly committed to our clients and other stakeholders for providing customized research services of the highest quality all the while being an organisation that’s trusted for its integrity, respected for its accountability, and admired for its excellence, by both clients and competitors alike.
Contact Us:
Abhishek Shukla
Sales Manager
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 9985550206
Mail: abhishek@marketdataforecast.com